Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Dec 1:14:410.
doi: 10.1186/1745-6215-14-410.

Platelet-rich plasma (PRP) in chronic epicondylitis: study protocol for a randomized controlled trial

Jose I Martin  1 , Josu Merino, Leire Atilano, Luis M Areizaga, Maria C Gomez-Fernandez, Natalia Burgos-Alonso, Isabel Andia
Affiliations
Randomized Controlled Trial

Platelet-rich plasma (PRP) in chronic epicondylitis: study protocol for a randomized controlled trial

Jose I Martin et al. Trials. .

Abstract

Background: Tendinopathy is a difficult problem to manage and can result in significant patient morbidity. Currently, the clinical use of platelet-rich plasma (PRP) in painful tendons is widespread but its efficacy remains controversial.

Methods/design: This study is a single-center, randomized double-blind controlled trial. Eighty patients will be allocated to have ultrasound (US)-guided needling combined with a leukocyte-depleted (that is, pure) PRP or lidocaine each alternate week for a total of two interventions. Outcome data will be collected before intervention, and at 6 weeks, 3, 6, and 12 months after intervention.

Main outcome measure: Changes in pain and activity levels, as assessed by Disabilities of the Arm, Shoulder and Hand (DASH-E, Spanish version) score, at 6 months. We will compare the percentage of patients in each group that achieve a successful treatment defined as a reduction of at least 25% in the DASH-E score. Secondary outcome measures include changes in DASH-E at 3 and 12 months, changes in pain as assessed by the visual analogue scale (VAS) at the 6-week, 3-, 6-, and 12-month follow-up, changes in sonographic features and neovascularity, and percentage of patients in each group with adverse reactions at 3, 6, and 12 months.

Discussion: The results of this study will provide insights into the effect of pure PRP in tendon and may contribute to identifying the best protocol for PRP application in tendinopathies.

Trial registration: ClinicalTrials.gov: NCT01945528.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study flow chart.
See this image and copyright information in PMC

References

    1. Maffulli N, Kha KM, Puddu G. Overuse tendon conditions: time to change a confusing terminology. Arthroscopy. 1998;14:840–843. doi: 10.1016/S0749-8063(98)70021-0. - DOI - PubMed
    1. Andia I, Sánchez M, Maffulli N. Tendon healing and platelet rich plasma therapies. Expert Opin Biol Ther. 2010;10:1415–1426. doi: 10.1517/14712598.2010.514603. - DOI - PubMed
    1. Andia I, Abate M. Platelet rich plasma injections for tendinopathy and osteoarthritis. Int J Clin Rheumatol. 2012;7:397–412. doi: 10.2217/ijr.12.36. - DOI
    1. Creaney L, Walla A, Curtis M, Connell D. Growth factor-based therapies provide additional benefit beyond physical therapy in resistant elbow tendinopathy: a prospective, double-blind, randomised trial of autologous blood injections versus platelet-rich plasma injections. Br J Sports Med. 2011;45:966–971. doi: 10.1136/bjsm.2010.082503. - DOI - PubMed
    1. Krogh TP, Fredberg U, Stengaard-Pedersen K, Christensen R, Jensen P, Ellingsen T. Treatment of lateral epicondylitis with platelet-rich plasma, glucocorticoid, or saline: a randomized, double-blind, placebo-controlled trial. Am J Sports Med. 2013;41:625–635. doi: 10.1177/0363546512472975. - DOI - PubMed

Publication types

Associated data